Air Transat Chooses Noveko(TM) Antimicrobial Technology for the Protection of
its Passengers and Employees
TSX: EKO
"The demand for our antimicrobial products in all our markets combined remains very strong. We are particularly proud to include an airline of Air Transat's scale among our clients and hope to develop this partnership over the longer term," indicated Alain Bolduc, President and Chief Operating Officer of the Company.
"Considering the current pandemic, Air Transat wishes to make all the means available to its passengers and employees in order to provide them with a healthier and safer environment. The innovative features of Noveko(TM) antimicrobial products and their superior protection led to their selection as a solution to a contingency plan aimed at limiting the spreading of diseases," said
Furthermore, the Company confirms that discussions are still under way with Air Transat and the French company Aerosys Technologies to obtain the required certifications in order to equip Air Transat's aircraft fleet with filters incorporating Noveko's antimicrobial filtration technology. Other airlines have also shown an interest in equipping their aircraft with such filters.
Profiles
Air Transat is Canada's leading holiday travel airline, carrying some 3 million passengers annually. Air Transat operates a fleet of 18 Airbus A330s and A310s. Air Transat is a subsidiary of Transat A.T., an integrated international tour operator with more than 60 destination countries that distributes products in over 50 countries. A holiday travel specialist, Transat operates mainly in
Noveko International Inc. offers innovative solutions in the environmental and medical fields worldwide. Through its subsidiaries, the Company specializes primarily in the following business segments: the development, manufacturing and marketing of derivative products from its patented antimicrobial filtration technology, including air filters, surgical masks and respirators, along with other products with antimicrobial properties such as AZURO(TM) hand sanitizers - and the development, manufacturing and marketing of medical equipment, primarily portable real-time ultrasound scanners for use in human and veterinary medicine.
Certain statements set forth in this press release constitute forward-looking statements. In some cases, these statements are identified by the use of terms such as "may", "could", "might", "intend", "should", "expect", "project", "plan", "believe", "estimate" or other comparable variants. These statements are based on the information available at the time they are written, on assumptions made by management and on the expectations of management, acting in good faith, regarding future events, including those relating to economic conditions, fluctuations in exchange rates and operating expenses, and the absence of unusual events entailing supplementary expenditures. Although management considers these assumptions and expectations reasonable based on the information available at the time they are written, they could prove inaccurate. Forward-looking statements are also subject, by their very nature, to known and unknown risks and uncertainties such as those related to the industry, acquisitions, labor relations, credit, key officers, supply and product liability. The actual results of Noveko International Inc. could differ materially from those indicated or underlying these forward-looking statements. The reader is therefore recommended not to unduly rely on these forward-looking statements. Forward-looking statements do not reflect the potential impact of special items, any business combination or any other transaction that may be announced or occur subsequent to the date hereof. The Company undertakes no obligation to update or revise the forward-looking statements to account for new events or new circumstances, except where provided for by applicable legislation.
For further information: Chantal Vennat, Director, Investor Relations, and Corporate Communications, Noveko International Inc., (514) 875-0606, http://www.noveko.com
Share this article